Comparative Pharmacology
Head-to-head clinical analysis: ACTIQ versus EXALGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIQ versus EXALGO.
ACTIQ vs EXALGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
None Documented
None Documented
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic